scholarly journals Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage 3 non-small cell lung cancer: safety and efficacy

2021 ◽  
pp. 100251
Author(s):  
Sally C.M. Lau ◽  
Malcolm Ryan ◽  
Jessica Weiss ◽  
Aline Fusco Fares ◽  
Miguel Garcia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Concurrent Chemoradiation ◽  
Small Cell Lung ◽  
Safety And Efficacy ◽  
Unresectable Stage

Concurrent Chemoradiation in Inoperable, Locally Advanced Non-small Cell Lung Cancer — Comparison of Efficacy and Toxicity in the Elderly

2012 ◽  
Vol 08 (01) ◽  
pp. 24 ◽  
Author(s):  
Christine Collen ◽  
Denis Schallier ◽  
Mark De Ridder ◽  
◽  
◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
The Elderly ◽  
Small Cell ◽  
Concurrent Chemoradiation ◽  
Small Cell Lung ◽  
Sequential Administration

Clinicians are faced with the challenge of treating increasing numbers of elderly patients with locally advanced non-small cell lung cancer (LA-NSCLC) and co-morbid conditions. The benefit of combined chemoradiation in the younger patient using the concurrent modality compared with the sequential administration of both modalities has been established in several randomised trials and recent meta-analyses. Because of the underrepresentation of elderly patients in clinical trials on concurrent chemoradiation (CCRT) in LA-NSCLC, treatment guidelines for this age group are not well established. The objective of this report is to summarise the data on efficacy and toxicity of CCRT in the elderly.

Sign in / Sign up

Export Citation Format

Share Document